



ABN 53 075 582 740

ASX ANNOUNCEMENT

8 November 2016

Bionomics Limited (ASX:BNO, OTCQX: BNOEF) hereby gives notice to the Australian Securities Exchange ("ASX") that shareholders of the company passed all resolutions considered before the Annual General Meeting today.

The Notice of Annual General Meeting and accompanying documents were lodged with ASX on 7 October 2016.

This notice is given in accordance with ASX Listing rule 3.13.2 and section 251AA of the Corporations Act 2001.

Resolution Number	Resolutions	Result	Proxy Votes			
			For	Against	Abstain	Proxy's discretion
1	Adoption of Remuneration Report	Carried unanimously on a show of hands	103,312,465	3,432,156	37,303,448	35,268,583
2	Re-election of Non-Executive Director – Dr Errol De Souza	Carried unanimously on a show of hands	143,125,297	889,168	382,548	35,298,621
3	Election of Non- Executive Director Mr Peter Turner	Carried unanimously on a show of hands	142,865,491	881,500	635,748	35,312,895
4	Election of Non- Executive Director Mr David Wilson	Carried unanimously on a show of hands	142,821,875	910,031	648,107	35,315,621
5.	Election of Non- Executive Director Mr Alan Fisher	Carried unanimously on a show of hands	141,483,450	1,983,456	648,107	35,580,621
6.	Approval of Proposed Issue of Share Options to Dr Errol De Souza	Carried unanimously on a show of hands	136,107,534	7,071,810	809,686	35,439,906
7.	Approval of Proposed Issue of Share Options to Mr Peter Turner	Carried unanimously on a show of hands	136,075,608	7,039,377	874,045	35,439,906
8.	Approval of Proposed Issue of Share Options to Mr David Wilson	Carried unanimously on a show of hands	136,059,108	7,039,377	1,074,045	35,256,406

9.	Approval of Proposed Issue of Share Options to Mr Alan Fisher	Carried unanimously on a show of hands	136,061,108	7,037,377	1,074,045	35,256,406
10.	Approval of Proposed Issue of Share Options to Dr Deborah Rathjen – Long Term Incentive	Carried unanimously on a show of hands	137,634,810	5,854,179	683,541	35,256,406
11.	Approval of Proposed Issue of Share Options to Dr Deborah Rathjen – Commercialisation Incentive	Carried unanimously on a show of hands	137,815,885	5,625,320	717,992	35,269,739

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+61 8 8354 6101
drathjen@bionomics.com.au

Mr Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6181
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 is expected to enter clinical trials in the fourth quarter of 2015. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au